However, little is known about JA, which has an 8-cis, 10trans, 12-cis conjugated trienoic system 8) . JA constitutes 20％ of the fatty acid composition in the seed of Jacaranda mimosifolia, a tall tree that is classified in the bignoniaceae family. There are few reports on the biological effects of JA and none on the absorption and metabolism. Therefore, in this study, we investigated the effects of JA in normal ICR mice.
An oral dose of JA of 5 mg/day for 1 week had no effects on body weight, food intake and tissue weight of ICR mice, indicating that JA had no harmful effects. Measurement of the fatty acid composition in each tissue showed increases in saturated fatty acids (SFAs) such as palmitic acid (16:0) and stearic acid (18:0) and decreases in monounsaturated fatty acids (MUFAs) such as palmitoleic acid (16:1) and oleic acid (18:1) after JA treatment. It was hypothesized that these changes occurred because of inhibition of stearoyl coenzyme A desaturase (SCD) by JA. SCD is an endoplasmic reticulum (ER) enzyme that catalyzes the biosynthesis of MUFAs from SFAs 18) . Additionally, SCD is deeply related to biosynthesis of triacylglycerol 18) . Recently, inhibition of SCD has been shown to improve obesity and diabetes, which suggests that this enzyme may be an important target in prevention of metabolic syndrome 19, 20) . The desaturation index of liver and white adipose tissue is used as an indicator of SCD activity, and we found that this index was decreased by JA, indicating that JA inhibited SCD activity. JA also decreased the expression of SCD-1 mRNA. Therefore, the results of this study revealed that JA inhibits SCD-1 mRNA expression and SCD activity in ICR mice, which suggests that JA may be effective for preventing obesity and diabetes.
EXPERIMENTAL PROCEDURES 2.1 Materials
Trimethylsilyldiazomethane (10％ in hexane, v/v) was purchased from GL Sciences, Inc. (Tokyo, Japan) . Sodium methoxide/methanol (1 mol/L solutions) and soy bean oil were purchased from Wako Pure Chemicals Industries (Osaka, Japan) . Jacaranda seed oil was a kind gift from the Miyazaki Prefectural Government (Miyazaki, Japan) . Jacaric acid (99％ purity) was purchased from Larodan Fine Chemicals AB (Malmö, Sweden) .
Methods

Animals and treatments
All procedures were performed in accordance with the Animal Experiment Guidelines of Tohoku University. The animal protocol was approved by the Animal Use Committee at Tohoku University 9, 10) . Male ICR mice (4 weeks of age) were obtained from Japan Clea (Tokyo, Japan) . A commercial diet (CE-2) was purchased from Japan Clea.
The composition of CE-2 was 8.9％ moisture, 24.9％ crude protein, 4.6％ crude fat, 4.1％ crude fiber, 6.6％ crude ash, and 51.0％ nitrogen free extract (w/w) . The fatty acid composition of CE-2 was 16.3％ palmitic acid (16:0) , 2.1％ stearic acid (18:0) , 21.0％ oleic acid ［18:1 (n-9) ］ , 44.4％ linoleic acid ［18:2 (n-6) ］ , 3.3％ α-linolenic acid ［18:3 (n-3) ］ , 2.3％ eicosapentaenoic acid, 1.3％ docosahexaenoic acid, and 9.4％ others (w/w) . After acclimatization for 1 week, mice were randomly divided into a control group (n＝6) and a JA group (n＝6) . Mice in these groups were subsequently administered soy bean oil and jacaranda seed oil, respectively. Each mouse received 50 μL test oil orally and forcibly every day (Table 1) . JA was not detectable in the soy bean oil. In the JA group, the test oil was a mixture of soy bean oil and jacaranda seed oil (21.4:41.1 vol/vol) such that JA was administered at 5 mg/day. After administration of the test oil for 1 week, the mice were weighed and then sacrificed by decapitation. Serum, brain, kidney, liver, lung, pancreas, spleen, and white adipose tissue (eWAT) were weighed and stored at -80℃ until assayed.
Gas chromatography (GC) analysis
Each tissue was homogenized with four volumes of saline. Total lipids from each homogenate and serum were extracted using the Bligh & Dyer procedure 21) . A volume of 2 mL of MeOH:CHCl 3
(2:1 v/v, containing butylated hydroxytoluene (BHT) ) was added to 400 μL of homogenate and mixed by vortex for 2 min. Then 1 mL of MeOH:CHCl 3 (1:1 v/v, containing BHT) was added, mixed by vortex for 2 min, and centrifuged for 5 min at 4℃ and 907g (Takara Tomy, Japan) . The lower layer was transferred to another tube and 1 mL of CHCl 3 containing BHT was added to the upper layer, mixed by vortex for 2 min, and centrifuged. This step was repeated three times. Total lipids were dried under a stream of nitrogen gas. A known amount of heptadecanoic acid (17:0) (Sigma, Steinheim, Germany) was added to each test fatty acid as an internal standard and the mixture was methylated with trimetylsilyldiazomethane for 30 min and sodium methoxide/methanol for 10 min at room temperature to prepare fatty acid methylesters 22, 23) . The product was subjected to gas chromatography (GC-2014, Shimadzu, Kyoto, Japan) using a flame ionization detector and a Supelcowax-10 fused silica capillary column (60 m×0.32 mm, 0.25 μm film thickness, Supelco, Bellefonte, PA) . The GC conditions were programmed as described previously 9, 24) . To identify JA, a reference standard of JA was used. To measure fatty acids, heptadecanoic acid (17:0) was used as described previously 25) .
mRNA expression analysis
A quantitative reverse transcriptase-PCR assay was conducted on total RNA extracted from liver using an RNeasy mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer' s protocol 26, 27) . The expression levels of stearoyl-CoA desaturase 1 (SCD-1) , fatty acid synthase (FAS) , acetyl-CoA carboxylase (ACC) and sterol regulatory element binding factor 1 (SREBP-1c) mRNA in the liver and eWAT were determined with a Thermal Cycler Dice Real Time System (Takara Bio, Shiga, Japan) , which allowed real-time quantitative detection of the PCR products by measuring the increase in fluorescence caused by binding of SYBR green to double-stranded DNA. In brief, cDNA was made from the total RNA in the liver and eWAT using a Prime-Script RT Master Mix (Perfect Real Time) kit (Takara) . The cDNA was subjected to PCR amplification with SYBR Premix Ex Taq (Takara) and a gene-specific primer for ACC, FAS, SCD-1, and SREBP-1c or β -actin (Table 1) . Amplification was performed with an activation step at 95℃ for 10 s, followed by 40 cycles at 95℃ for 5 s (denaturation) and 60℃ for 31 s (extension) , and a dissociation stage at 95℃ for 15 s, 60℃ for 30 s and 95℃ for 15 s. The β-actin content in each sample was used to normalize the results.
Triacylglycerol levels in serum and liver
Triacylglycerol levels in serum and liver were measured using commercial enzyme kits (Wako Pure Chemical, Osaka, Japan) according to the manufacturer' s protocol as described previously 25, 26) .
Statistical analysis
Each result is shown as the mean±SE. A two-tailed unpaired Student t-test was performed to compare the findings between groups. A difference was considered to have significance at p＜0.05 and p＜0.01.
RESULTS
Effects of jacaric acid on body weight, food intake
and tissue weight in ICR mice Body weight, food intake and tissue weight were measured to examine the influence of JA on growth parameters of ICR mice (Table 3 ) . There were no significant differences in body weight, food intake and tissue weight between the JA and control groups, indicating that JA did not influence the growth of ICR mice.
Uptake of jacaric acid and fatty acid composition of tissues in ICR mice
The fatty acid composition of serum, brain, kidney, liver, lung, pancreas, spleen and eWAT were measured in ICR mice (Tables 4-11 ) . JA was detected in serum, kidney, liver, lung and eWAT, but not in brain, pancreas and spleen. The JA levels in the tissues in the JA group (Table 12) were 0.008 mmol/L in serum and 0.009, 0.015, 0.001, and 7.667 μmol/g in kidney, liver, lung and eWAT, respectively, indicating that JA was systemically absorbed and localized mainly in eWAT. The amounts of SFA 18:0 in liver and eWAT were significantly higher in the JA group, with levels of 125.9％ and 117.1％ of the respective value in the control group (taken to be 100％) . SFA 16:0 in eWAT in the JA group showed a tendency to be higher, at 102.4％ com- 18:1 (n-9) 5.5±0.2 6.2±0. 78.1％ compared with the control group (p＝0.107) . These results suggest that JA inhibited Δ9 desaturation in fatty acid synthesis. This hypothesis was tested using the desaturation index (ratio of 16:1/16:0 or 18:1/18:0 fatty acids) (Fig. 1) . The 16:1/16:0 desaturation indexes of brain, liver and eWAT in the JA group showed a tendency to decrease compared with the control group (p＝0.089, 0.109 and 0.081, respectively) and the 18:1/18:0 desaturation indexes of liver and eWAT were significantly decreased in the JA group. These findings show that JA inhibited Δ9 desaturation in liver and white adipose tissue. The desaturation index is a measure of SCD activity, and therefore the changes in this index suggested that JA inhibited SCD activity.
3.3 Expression of SCD-1 mRNA in mice after administration of jacaric acid Since JA decreased the desaturation index, we investigated whether JA affected the expression level of SCD-1 mRNA. The SCD-1 mRNA level in liver of the JA group was significantly lower than that of the control group (Fig. 2) , consistent with the inhibition of SCD activity by JA. The mRNA levels of FAS, ACC, and SREBP-1c, all of which are genes related to fatty acid synthesis, also showed a tendency to decrease in liver of the JA group compared to the control group (p＝0.17, 0.28, and 0.07, respectively) (Fig.  2) . These results suggest that JA suppressed not only SCD-1 expression, but also the whole of the fatty acid synthesis system. In addition, The SCD-1 mRNA level in eWAT of the JA group (0.52±0.10) showed a tendency to decrease compared to the control group (1.00±0.26) (p＝ 0.15) , consistent with the inhibition of SCD activity by JA.
Triacylglycerol levels in serum and liver of mice after
administration of jacaric acid The triacylglycerol levels of serum and liver were measured in ICR mice. The serum triacylglycerol level in the JA group (0.73±0.19 mmol/L) showed a tendency to decrease compared to the control group (1.07±0.12 mmol/L) (p＝ 0.16) . The liver triacylglycerol level in the JA group (40.5± 9.0 μmol/g) showed a tendency to decrease compared to the control group (65.0±9.0 μmol/g) (p＝0.08) . There is a possibility that JA suppressed not only SCD-1 expression, but also lipid accumulation in the liver.
DISCUSSION
In this study, we showed for the first time that SCD activity in liver of ICR mice is inhibited by JA. The levels of SFAs, especially 18:0, in liver and eWAT were significantly increased (Table 7 ) and the levels of MUFAs, especially 18:1, were significantly decreased in the liver and spleen after treatment with JA ( Table 7 and 10) . Given these changes, the desaturation index (18:1/18:0) in liver and eWAT was significantly decreased by JA (Fig. 1) . This suggests that JA inhibits Δ9 desaturation in the liver and white adipose tissue through inhibition of SCD, since the desaturation index reflects the SCD activity.
SCD is an ER enzyme that catalyzes biosynthesis of MUFAs from SFAs that are either synthesized de novo or derived from the diet 18) . Additionally, SCD is deeply related to biosynthesis of triacylglycerol 18) . There are four SCD isoforms in mouse (SCD-1, SCD-2, SCD-3 and SCD-4) . SCD-1 is expressed in WAT, brown adipose tissue, liver and heart, in response to diet 18) . Humans express two Δ9 desaturase genes, designated SCD-1 and SCD-5, with SCD-1 exhibiting nearly ubiquitous expression and SCD-5 being restricted primarily to the brain and pancreas. Many reports have shown that inhibition of SCD activity might be of benefit for treatment of obesity, diabetes, liver steatosis and other diseases associated with metabolic syndrome 19, 20) . Therefore, pharmacological control of SCD activity has become a target in prevention of obesity and diabetes.
CLA prevents liver steatosis in adult Wistar rats by inhibition of fatty acid synthesis 28) . This effect has been proposed to be due to reduction of SCD-1 mRNA expression and SCD activity by CLA, through a mechanism that is still not clear. However, it is likely that CLA binds to the active site or to an unidentified allosteric site on the SCD enzyme 29) . JA also has a conjugated double bond and may inhibit SCD through a mechanism similar to that of CLA. In addition, fatty acid synthesis system genes such as SCD-1 and FAS are regulated by SREBP-1c, and PUFAs modulates SCD-1 by directly inhibiting SREBP-1c transcription 30) . In this study, we found that the mRNA levels of SCD-1, FAS, ACC, and SREBP-1c were decreased in mice treated with JA compared to controls, with a significant difference for SCD-1 in liver, a tendency for a difference for FAS, ACC and SREBP-1c in liver, and a tendency for a difference for SCD-1 in eWAT. The decreased expression of genes related to fatty acid synthesis suggests that JA might directly inhibit SREBP-1c transcription in a similar manner to PUFAs. Regardless of the exact mechanism, this is the first report to show that JA inhibits SCD activity.
Isoflavone (daidzein) has been shown to reduce body weight and obesity via a decrease of SCD-1 mRNA expression 31) . Therefore, JA may reduce obesity by inhibiting SCD-1 mRNA expression or SCD activity. In this study, the eWAT weight in the JA group was 76％ of that in the control group, and showed a tendency to decrease (p＝ 0.101) ( Table 3 ) . In addition, the serum and liver triacylglycerol levels in the JA group showed a tendency to decrease compared to the control group. There was no difference in the change in body weights between the two groups, but this may have been because the study period was short. Longer-term ingestion of JA may have an antiobesity effect and other beneficial physiological properties. However, recent studies have also shown potentially harmful consequences of SCD inhibition 20) , and therefore further studies are needed to examine the safety of JA.
In this study, JA was detected in serum, kidney, liver, lung and eWAT, indicating systemic absorption after oral delivery ( Table 12 ) . Uptake of JA was the largest in eWAT, followed by liver. We previously showed that α-ESA (9c, 11t, 13t-18:3) and punicic acid (9c, 11t, 13c-18:3) , which both have a conjugated triene system, are absorbed in rats 23, 25) . This study provides the first evidence that JA (8c, 10t, 12c-18:3) is absorbed in mice. There were no negative side effects of oral JA at 5 mg/day for 1 week on body weight, food intake and tissue weight of ICR mice. Thus, JA did not exhibit toxicity, consistent with reports showing that other CLnAs are also non-toxic in vivo 9, 32) . However, the long term biological effects of JA are unclear and the safety of JA requires further investigation. 
CONCLUSION
The results of this study show that JA inhibits SCD activity in ICR mice. Inhibition of SCD may have anti-obesity and anti-diabetes effects. Therefore JA may be useful in this kind of treatment, particularly since JA was systemically absorbed and did not exhibit toxicity in the current study. However, the effects of long term intake at an adequate dose will have to be examined before beneficial uses of JA can be established.
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